Form 4: Alumis CMO Jorn Drappa Receives Significant Equity Grant

Alumis Inc.'s Chief Medical Officer, Jorn Drappa, was granted 25,450 restricted stock units and 101,850 stock options, aligning executive compensation with long-term company performance.

Summary

• Chief Medical Officer Jorn Drappa acquired 25,450 shares of common stock, representing a restricted stock unit (RSU) grant, with a transaction price of $0.
• These RSUs will vest 25% on August 1, 2026, and the remainder in equal quarterly installments over the subsequent 12 quarters, contingent on continuous service.
• Drappa also acquired 101,850 stock options with an exercise price of $3.95 per share.
• These stock options will vest 25% on July 29, 2026, and the remaining shares in equal monthly installments over the following 36 months, subject to continuous service.
• Following these transactions, Drappa beneficially owns 28,450 shares of common stock and 101,850 stock options.
• The common stock total includes 3,000 shares acquired on May 20, 2025, through the Issuer's 2024 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The filing reports a significant equity grant to a key executive, which is a positive sign for executive retention and alignment of interests with shareholders. It does not contain any negative financial or operational news.

Positives

• The equity grants (RSUs and stock options) align the Chief Medical Officer's interests with long-term shareholder value creation.
• The grants serve as a retention mechanism for key executive talent.
• The acquisition of 3,000 shares via the Employee Stock Purchase Plan indicates management's direct investment in the company.

Risks

• The vesting of RSUs and stock options is subject to the Reporting Person's Continuous Service, meaning forfeiture if employment ceases before vesting.

Future Outlook

The equity grants are structured with multi-year vesting schedules, indicating a long-term commitment to the Chief Medical Officer's role and the company's future performance.

Industry Context

Equity grants to key executives like the Chief Medical Officer are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize top talent, aligning their compensation with the long-term success and clinical development milestones of the company.

Comparison to Industry Standards

• Executive equity compensation packages, including a mix of restricted stock units and stock options with multi-year vesting, are common across the biotech and pharmaceutical sectors.
• While specific grant sizes vary based on company stage, market capitalization, and executive role, the structure observed here is consistent with typical industry practices for a Chief Medical Officer at a publicly traded company like Alumis Inc.

Corporate Governance

Related Party Transactions

• This filing reports an equity grant to a Chief Medical Officer, which is a related party transaction as it involves compensation to an executive of the company.

Stakeholder Impact

• Shareholders: The grants align the Chief Medical Officer's incentives with shareholder value, potentially leading to better long-term performance. Dilution from future share issuance upon vesting/exercise is a consideration.
• Employees: The existence of an Employee Stock Purchase Plan (ESPP) and equity incentive plans suggests a broader framework for employee compensation and participation in company success.

Next Steps

• Continued vesting of 25% of restricted stock units on August 1, 2026, followed by equal quarterly installments over 12 quarters.
• Continued vesting of 25% of stock options on July 29, 2026, followed by equal monthly installments over 36 months.
• Ongoing continuous service by the Reporting Person is required for vesting.

Key Dates

Recommendation

This Form 4 filing reports a standard equity compensation grant to a key executive, which is generally a positive for aligning management incentives with shareholder interests. However, it does not contain new material information about the company's financial performance, strategic direction, or operational results that would warrant a change in investment recommendation. It reinforces the status quo of executive compensation practices.

Keywords

Alumis Inc., ALMS, Jorn Drappa, Chief Medical Officer, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Employee Stock Purchase Plan